9M 2023 Financial Performance
9M 2023: APPENDIX
MAGLI program - Potential first-in-
class endocannabinoid therapy
MAGLI mode of action
28
2-AG
MAGL
CB
Restore neuronal
transmission
OH
OH
G(ilo)
Ner
ve
CB2
Reduce inflammation
OH
Gilo)
Glia
arachidonic acid
LOH
HO
HO
ОН
prostaglandin E2
OH
OH
OH
OH
prostaglandin D2 thromboxane A2
MAGL: monoacylglycerol lipase; 2-AG: 2-arachidonoylglycerol; CB1: cannabinoid receptor 1; CB2: cannabinoid receptor 2
Medical condition
•
Multiple opportunities within psychiatry and
neurology
Molecule
•
•
Inhibitor of the monoacylglycerol lipase
(MAGL) and selective modulator of the
endocannabinoid system
Clinical development phase
Clinical development program in phase I
•
Multiple assets with varying degree of
CNS penetranceView entire presentation